cidofovir anhydrous has been researched along with Cancer of the Vulva in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bevilacqua, F; Bleeker, MCG; Bornstein, J; Carcopino, X; Chargari, C; Cruickshank, ME; Erzeneoglu, BE; Esat Temiz, B; Gallio, N; Gultekin, M; Heller, D; Joura, E; Kesic, V; Planchamp, F; Preti, M; Querleu, D; Reich, O; Stockdale, CK; Van Beurden, M; Vieira-Baptista, P; Woelber, L; Zodzika, J | 1 |
| Alvarez-Mendoza, C; Hurt, CN; Jones, S; Nedjai, B; Powell, N; Tristram, A | 1 |
| Bryant, D; Fiander, AN; Hibbitts, S; Hurt, CN; Jones, SEF; Powell, N; Tristram, AJ | 1 |
| Carucci, M; Fiander, A; Hurt, CN; Jones, S; Madden, TA; Naik, R; Nordin, AJ; Powell, N; Tristram, A | 1 |
| Helm, CW | 1 |
| Mahner, S; Wölber, L | 1 |
| Dutton, P; Fiander, A; Griffiths, G; Hibbitts, S; Hurt, CN; Jones, S; Madden, T; Man, S; Naik, R; Nordin, AJ; Powell, N; Tristram, A | 1 |
| Bryant, A; Kaushik, S; Lawrie, TA; Nordin, A; Pepas, L | 1 |
| Bryant, A; Chakrabarti, M; Kaushik, S; Lawrie, TA; Nordin, A; Pepas, L | 1 |
| Calista, D | 1 |
| Gormley, RH; Kovarik, CL | 1 |
| Aboulafia, D; Berry, JM; Da Costa, M; Darragh, TM; Einstein, MH; Goldstone, SE; Jay, N; Lee, JY; Palefsky, JM; Panther, L; Stier, EA; Wilkin, T | 1 |
| Fiander, A; Tristram, A | 1 |
| Bossens, M; DeClercq, E; Freedman, R; Kavanagh, J; Koonsaeng, S; Kudelka, A; Sittisomwong, T; Snoeck, R; Verschraegen, C | 1 |
3 review(s) available for cidofovir anhydrous and Cancer of the Vulva
| Article | Year |
|---|---|
Medical interventions for high-grade vulval intraepithelial neoplasia.
Topics: Administration, Topical; Adult; Aminoquinolines; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma in Situ; Cidofovir; Cytosine; Female; Humans; Imiquimod; Indoles; Organophosphonates; Randomized Controlled Trials as Topic; Vulvar Neoplasms | 2015 |
Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia.
Topics: Adult; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Cidofovir; Cytosine; Disease Progression; Female; Humans; Imiquimod; Indoles; Laser Therapy; Neoplasm Recurrence, Local; Organophosphonates; Photochemotherapy; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Vulvar Neoplasms | 2016 |
Human papillomavirus-related genital disease in the immunocompromised host: Part II.
Topics: Adjuvants, Immunologic; Alphapapillomavirus; Aminoquinolines; Antineoplastic Agents, Phytogenic; Antiviral Agents; Anus Neoplasms; Buschke-Lowenstein Tumor; Catechin; Caustics; Cidofovir; Condylomata Acuminata; Counseling; Cryotherapy; Cytosine; Female; Humans; Imiquimod; Immunocompromised Host; Male; Ointments; Organophosphonates; Papillomavirus Infections; Penile Neoplasms; Podophyllotoxin; Precancerous Conditions; Treatment Outcome; Trichloroacetic Acid; Vaginal Neoplasms; Vulvar Neoplasms; Warts | 2012 |
5 trial(s) available for cidofovir anhydrous and Cancer of the Vulva
| Article | Year |
|---|---|
Combined HPV 16 E2 and L1 methylation predict response to treatment with cidofovir and imiquimod in patients with vulval intraepithelial neoplasia.
Topics: Aminoquinolines; Biomarkers; Cidofovir; DNA Methylation; Female; Human papillomavirus 16; Humans; Imiquimod; Papillomavirus Infections; Prospective Studies; Uterine Cervical Neoplasms; Vulvar Neoplasms | 2022 |
Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN).
Topics: Administration, Topical; Antineoplastic Agents; Carcinoma in Situ; Cidofovir; Female; Humans; Imiquimod; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome; Vulvar Neoplasms | 2018 |
Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial.
Topics: Adult; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cidofovir; Cytosine; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imiquimod; Middle Aged; Neoplasm Grading; Organophosphonates; Vulvar Neoplasms | 2014 |
Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.
Topics: Acquired Immunodeficiency Syndrome; Administration, Cutaneous; Adult; Aged; Antiviral Agents; Anus Neoplasms; Carcinoma in Situ; CD4 Lymphocyte Count; Cidofovir; Cyclin-Dependent Kinase Inhibitor p16; Cytosine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Proteins; Organophosphonates; Perineum; Prospective Studies; Vulvar Neoplasms | 2013 |
Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Carcinoma in Situ; Cidofovir; Cytosine; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organophosphonates; Vulvar Neoplasms | 2005 |
6 other study(ies) available for cidofovir anhydrous and Cancer of the Vulva
| Article | Year |
|---|---|
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statem
Topics: Carcinoma in Situ; Cidofovir; Colposcopy; Female; Genital Neoplasms, Female; Humans; Imiquimod; Melanoma; Melanoma, Cutaneous Malignant; Paget Disease, Extramammary; Pregnancy; Skin Neoplasms; Vulvar Neoplasms | 2022 |
Human Papillomavirus DNA Methylation Predicts Response to Treatment Using Cidofovir and Imiquimod in Vulval Intraepithelial Neoplasia 3.
Topics: Aminoquinolines; Biomarkers; Carcinoma in Situ; Cidofovir; Cytosine; DNA Methylation; DNA, Viral; Drug Therapy, Combination; Female; Genes, Viral; Humans; Imiquimod; Neoplasm Staging; Organophosphonates; Papillomaviridae; Papillomavirus Infections; Promoter Regions, Genetic; ROC Curve; Treatment Outcome; Vulvar Neoplasms | 2017 |
Is cidofovir a better treatment than imiquimod for high-grade vulval intraepithelial neoplasia?
Topics: Carcinoma in Situ; Cidofovir; Female; Humans; Imiquimod; Neoplasm Recurrence, Local; Vulvar Neoplasms | 2018 |
Surgery or topical therapy for vulval intraepithelial neoplasia.
Topics: Aminoquinolines; Carcinoma in Situ; Cidofovir; Cytosine; Female; Humans; Imiquimod; Organophosphonates; Vulvar Neoplasms | 2014 |
Topical 1% cidofovir for the treatment of vulvar intraepidermal neoplasia (VIN1) developed on lichen sclerosus.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Cidofovir; Cytosine; Female; Humans; Organophosphonates; Precancerous Conditions; Vulvar Lichen Sclerosus; Vulvar Neoplasms | 2009 |
Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir.
Topics: Administration, Oral; Administration, Topical; Adult; Antineoplastic Agents; Carcinoma in Situ; Cidofovir; Cytosine; Drug Resistance, Multiple; Female; Humans; Injections, Subcutaneous; Interferons; Isotretinoin; Neoplasm Recurrence, Local; Organophosphonates; Organophosphorus Compounds; Uterine Cervical Dysplasia; Vulvar Neoplasms | 2001 |